Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Published Online
on June 25, 2009

Stroke. 2009
Published online before print June 25, 2009, doi: 10.1161/STROKEAHA.109.554378
A more recent version of this article appeared on September 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
40/9/3022    most recent
STROKEAHA.109.554378v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by van Rooden, S.
Right arrow Articles by van Buchem, M. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Rooden, S.
Right arrow Articles by van Buchem, M. A.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Amyloidosis
*MRI Scans
Related Collections
Right arrow CT and MRI
Right arrow Intracerebral Hemorrhage

Submitted on April 20, 2009
Accepted on May 20, 2009

Descriptive Analysis of the Boston Criteria Applied to a Dutch-Type Cerebral Amyloid Angiopathy Population

Sanneke van Rooden MSc*; Jeroen van der Grond PhD; Rivka van den Boom MD, PhD; Joost Haan MD, PhD; Jennifer Linn MD; Steven M. Greenberg MD, PhD; and Mark A. van Buchem MD, PhD

From the Departments of Radiology (S.v.R., J.v.d.G., R.v.d.B., M.A.v.B.) and Neurology (J.H.), Leiden University Medical Center, Leiden, The Netherlands; the Department of Neurology (J.H.), Rijnland Hospital, Leiderdorp, The Netherlands; the Department of Neuroradiology (J.L.), University Hospital Munich, Munich, Germany; and the Hemorrhagic Stroke Research Program (S.M.G.), Department of Neurology, Massachusetts General Hospital, Boston, Mass.

* To whom correspondence should be addressed. E-mail: S.van_Rooden{at}lumc.nl.

Background and Purpose—Validation of the Boston criteria for the in vivo diagnosis of cerebral amyloid angiopathy (CAA) is challenging, because noninvasive diagnostic tests do not exist. Hereditary cerebral hemorrhage with amyloidosis–Dutch type is an accepted monogenetic model of CAA and diagnosis can be made with certainty based on DNA analysis. The aim of this study was to analyze and refine the existing Boston criteria in patients with hereditary cerebral hemorrhage with amyloidosis–Dutch type.

Methods—We performed T2*-weighted MRI in 27 patients with hereditary cerebral hemorrhage with amyloidosis–Dutch type to assess the presence and location of microbleeds, intracranial hemorrhages, and superficial siderosis. Using the Boston criteria, subjects were categorized as having: no hemorrhages, possible CAA, probable CAA, and hemorrhagic lesions not qualifying for CAA. The sensitivity of the Boston criteria was calculated separately using intracranial hemorrhages only and using intracranial hemorrhages and microbleeds.

Results—The sensitivity of the Boston criteria for probable CAA increased from 48% to 63% when microbleeds were included. For symptomatic subjects only, the sensitivity was 100%. No hemorrhages were identified in the deep white matter, basal ganglia, thalamus, or brainstem. Superficial siderosis, observed in 6 patients, did not increase the sensitivity of the Boston criteria in our study group.

Conclusions—Our data show that using T2*-weighted MRI and including microbleeds increase the sensitivity of the Boston criteria. The exclusion of hemorrhages in the deep white matter, basal ganglia, thalamus, and brainstem does not lower the sensitivity of the Boston criteria.


Key words: cerebral amyloid angiopathy • hemorrhage • MRI • neuroradiology